Announced today that it offers shut on a $2 million expenditure from a fresh undisclosed private investor to bring its total financing to $9.25 million. This brand-new investment will convert to stock in the next substantial round of preferred equity funding. THE BUSINESS announced two additions to the senior administration team also. Simon S. Jones, Ph.D., was appointed Vice President, Biology and Preclinical Advancement and John H. Van Duzer, Ph.D., was appointed Vice President, Manufacturing and Chemistry. Acetylon is certainly applying its scientific expertise to the advancement of small molecule HDAC inhibitors that build upon the confirmed therapeutic potential of HDAC inhibition with enhanced target selectivity.Dr. Alireza Minagar and co-workers conducted a small trial involving 15 patients with the average age of 44.5 years with relapsing-remitting MS who had been taking interferon for at least six months and were experiencing symptoms and developing new brain lesions. The researchers suspect these unpredictable attacks may be triggered by an inappropriate response to viral or bacterial infections, with symptoms disappearing and appearing in a random manner. For a four month period the patients were given a 100mg a complete day of doxycycline, a known member of the tetracycline family of antibiotics, to take addition with their regular dosage of interferon.